REZOLUTE INC. - COMMON STOCK (NV)

Rezolute to Host Corporate Update Call on May 4, 2022

04 5 2022 16:01:00 提供 Nasdaq GlobeNewswire

Rezolute, Inc. Announces Closing of Registered Direct Offering

04 5 2022 09:33:12 提供 Nasdaq GlobeNewswire

Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

01 5 2022 23:25:14 提供 Nasdaq GlobeNewswire

Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

01 5 2022 14:00:00 提供 Nasdaq GlobeNewswire

RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022

26 4 2022 16:05:00 提供 Nasdaq GlobeNewswire

Rezolute Joins the Rare Disease Company Coalition

29 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism

23 3 2022 07:00:00 提供 Nasdaq GlobeNewswire

Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME

22 2 2022 07:00:02 提供 Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress

09 2 2022 16:05:00 提供 Nasdaq GlobeNewswire

Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress

12 11 2021 16:05:00 提供 Nasdaq GlobeNewswire

Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering

13 10 2021 08:10:40 提供 Nasdaq GlobeNewswire

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering

12 10 2021 16:05:00 提供 Nasdaq GlobeNewswire

Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021

22 9 2021 16:05:00 提供 Nasdaq GlobeNewswire

Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

15 9 2021 16:56:23 提供 Nasdaq GlobeNewswire

Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

09 9 2021 16:05:00 提供 Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Virtual Healthcare Conferences

07 9 2021 16:05:00 提供 Nasdaq GlobeNewswire

Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

10 8 2021 07:00:01 提供 Nasdaq GlobeNewswire

Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

04 5 2021 08:00:01 提供 Nasdaq GlobeNewswire

Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners

19 4 2021 08:00:01 提供 Nasdaq GlobeNewswire

Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021

22 3 2021 08:00:00 提供 Nasdaq GlobeNewswire